AR066701A1 - 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia - Google Patents
3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapiaInfo
- Publication number
- AR066701A1 AR066701A1 ARP080102179A ARP080102179A AR066701A1 AR 066701 A1 AR066701 A1 AR 066701A1 AR P080102179 A ARP080102179 A AR P080102179A AR P080102179 A ARP080102179 A AR P080102179A AR 066701 A1 AR066701 A1 AR 066701A1
- Authority
- AR
- Argentina
- Prior art keywords
- piridines
- imidazolil
- pirazolo
- therapy
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93294807P | 2007-05-22 | 2007-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066701A1 true AR066701A1 (es) | 2009-09-09 |
Family
ID=40075474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102179A AR066701A1 (es) | 2007-05-22 | 2008-05-22 | 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia |
| ARP170103074A AR110128A2 (es) | 2007-05-22 | 2017-11-06 | Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103074A AR110128A2 (es) | 2007-05-22 | 2017-11-06 | Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7629344B2 (enExample) |
| EP (1) | EP2155712B1 (enExample) |
| JP (1) | JP5457338B2 (enExample) |
| KR (1) | KR101534661B1 (enExample) |
| CN (1) | CN101743238B (enExample) |
| AR (2) | AR066701A1 (enExample) |
| AU (1) | AU2008256862B2 (enExample) |
| BR (1) | BRPI0811849A8 (enExample) |
| CA (1) | CA2687625C (enExample) |
| CL (1) | CL2008001493A1 (enExample) |
| CO (1) | CO6241152A2 (enExample) |
| DK (1) | DK2155712T3 (enExample) |
| EA (1) | EA015529B1 (enExample) |
| ES (1) | ES2600477T3 (enExample) |
| HU (1) | HUE032273T2 (enExample) |
| IL (1) | IL202248A (enExample) |
| JO (1) | JO3319B1 (enExample) |
| MA (1) | MA31442B1 (enExample) |
| MX (1) | MX2009012567A (enExample) |
| NZ (1) | NZ581405A (enExample) |
| PE (1) | PE20090293A1 (enExample) |
| PL (1) | PL2155712T3 (enExample) |
| PT (1) | PT2155712T (enExample) |
| TW (1) | TWI418353B (enExample) |
| UA (1) | UA99619C2 (enExample) |
| WO (1) | WO2008147815A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7777035B2 (en) * | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| PT2081921E (pt) | 2006-07-10 | 2010-12-10 | Paion Uk Ltd | Sais de benzodiazepina de acção curta e suas formas polimórficas |
| NZ581405A (en) * | 2007-05-22 | 2011-06-30 | Chemocentryx Inc | 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders |
| BRPI0918517B8 (pt) | 2008-09-11 | 2021-05-25 | Chemocentryx Inc | composto, composição farmacêutica, e, uso de um composto |
| EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
| EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| SG11201501479QA (en) * | 2012-08-27 | 2015-04-29 | Chemocentryx Inc | Antagonists of chemokine receptors |
| SG11201504410PA (en) * | 2012-12-07 | 2015-07-30 | Chemocentryx Inc | Diazole lactams |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| US20170195506A1 (en) * | 2015-12-30 | 2017-07-06 | Kabushiki Kaisha Toshiba | Image forming apparatus forming location free print system and print job retrieval method by the same |
| AU2017246460B2 (en) | 2016-04-07 | 2021-04-22 | Chemocentryx, Inc. | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス,インコーポレイティド | Pd-l1疾患の処置のためのヘテロアリール-ビフェニルアミド |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US715746A (en) * | 1902-02-25 | 1902-12-16 | Nat Tube Co | Apparatus for handling tube-plates. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| IE47467B1 (en) * | 1977-10-26 | 1984-03-21 | Wellcome Found | Imidazoline derivatives and their salts |
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4927942A (en) * | 1988-12-15 | 1990-05-22 | Texaco Chemical Co. | Method for the preparation of imidazoles |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7842693B2 (en) * | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
| US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| KR101255356B1 (ko) * | 2002-06-12 | 2013-04-17 | 케모센트릭스, 인크. | 염증 및 면역 질병의 치료를 위한 ccr1 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7435830B2 (en) * | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7777035B2 (en) * | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| EA017278B9 (ru) * | 2005-06-22 | 2013-01-30 | Кемосентрикс, Инк. | Соединения азаиндазола и способы применения |
| KR200434921Y1 (ko) * | 2006-07-10 | 2007-01-02 | 서용석 | 야외용 간이 화장실 |
| NZ581405A (en) * | 2007-05-22 | 2011-06-30 | Chemocentryx Inc | 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders |
-
2008
- 2008-05-21 NZ NZ581405A patent/NZ581405A/en unknown
- 2008-05-21 MX MX2009012567A patent/MX2009012567A/es active IP Right Grant
- 2008-05-21 AU AU2008256862A patent/AU2008256862B2/en active Active
- 2008-05-21 BR BRPI0811849A patent/BRPI0811849A8/pt not_active IP Right Cessation
- 2008-05-21 US US12/124,894 patent/US7629344B2/en active Active
- 2008-05-21 EA EA200901572A patent/EA015529B1/ru not_active IP Right Cessation
- 2008-05-21 PT PT87560546T patent/PT2155712T/pt unknown
- 2008-05-21 EP EP08756054.6A patent/EP2155712B1/en active Active
- 2008-05-21 ES ES08756054.6T patent/ES2600477T3/es active Active
- 2008-05-21 WO PCT/US2008/064374 patent/WO2008147815A1/en not_active Ceased
- 2008-05-21 CA CA2687625A patent/CA2687625C/en active Active
- 2008-05-21 JP JP2010509526A patent/JP5457338B2/ja active Active
- 2008-05-21 KR KR1020097026765A patent/KR101534661B1/ko active Active
- 2008-05-21 UA UAA200913250A patent/UA99619C2/ru unknown
- 2008-05-21 DK DK08756054.6T patent/DK2155712T3/en active
- 2008-05-21 PL PL08756054T patent/PL2155712T3/pl unknown
- 2008-05-21 CN CN200880024760.9A patent/CN101743238B/zh active Active
- 2008-05-21 HU HUE08756054A patent/HUE032273T2/en unknown
- 2008-05-22 PE PE2008000878A patent/PE20090293A1/es not_active Application Discontinuation
- 2008-05-22 TW TW097118925A patent/TWI418353B/zh active
- 2008-05-22 AR ARP080102179A patent/AR066701A1/es not_active Application Discontinuation
- 2008-05-22 CL CL200801493A patent/CL2008001493A1/es unknown
- 2008-05-22 JO JOP/2008/0231A patent/JO3319B1/ar active
-
2009
- 2009-11-12 US US12/617,620 patent/US7960388B2/en active Active
- 2009-11-19 IL IL202248A patent/IL202248A/en active IP Right Grant
- 2009-11-20 CO CO09132269A patent/CO6241152A2/es active IP Right Grant
- 2009-12-14 MA MA32416A patent/MA31442B1/fr unknown
-
2011
- 2011-05-09 US US13/103,993 patent/US8481545B2/en active Active
-
2013
- 2013-01-04 US US13/734,479 patent/US20130184289A1/en not_active Abandoned
-
2017
- 2017-11-06 AR ARP170103074A patent/AR110128A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066701A1 (es) | 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia | |
| EA017278B9 (ru) | Соединения азаиндазола и способы применения | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| WO2008008374A3 (en) | Ccr2 inhibitors and methods of use thereof | |
| EA200900168A1 (ru) | Триазолил фенилбензолсульфонамиды | |
| EA201000341A1 (ru) | 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| EA201400392A1 (ru) | ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb | |
| MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
| MX2009000900A (es) | Derivados de imidazolonas sustituidas, preparacion y usos. | |
| BR112015012842A2 (pt) | diazol lactamas | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| WO2007044804A3 (en) | Piperidine derivatives and methods of use | |
| ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
| BRPI0517963A2 (pt) | piridinureas antralinamidas como inibidores de receptores de cinases do fator de crescimento endotelial vascular | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| CL2011002965A1 (es) | Compuestos derivados de piperidinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso de dichos compuestos para el tratamiento y/o profilaxis de trastornos cardiovasculares, tromboembolicos y/o tumores. | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| MX2009000762A (es) | 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central. | |
| CL2008002696A1 (es) | Compuestos derivados de hidroxi-benzamidas, antagonistas de receptores muscarinicos; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; y uso del compuesto para el tratamiento de enfermedades de las vias respiratorias obstructivas o inflamatorias, broncoconstriccion, asma, bronquitis. | |
| WO2007109615A3 (en) | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS | |
| WO2014035967A3 (en) | Antagonists of chemokine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |